Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
Want to see BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
$2.45
-$0.02(-10.62%)
At close: 4:00 PM EST
$2.45
-$0.02(-10.62%)
Day’s Range― - ―
52-Week Range$2.15 - $5.06
Previous CloseN/A
Volume8.80M
Average Volume (3M)23.61K
Market Cap
$14.18M
Enterprise Value$19.91M
Total Cash (Recent Filing)$17.35M
Total Debt (Recent Filing)$9.07M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 13, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding4,368,295
10 Day Avg. Volume24,146
30 Day Avg. Volume23,614
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.63
Price to Sales (P/S)9.57
P/FCF Ratio-1.39
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue14.19
Enterprise Value/Gross Profit18.98
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$12.00Price Target Upside389.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$1.72M
Bulls Say, Bears Say
Bulls Say
Commercial Traction For APHEXDA And Rising RoyaltiesPartner-driven APHEXDA royalties create a recurring, asset-backed revenue stream that rose materially in Q1 2026 (APHEXDA sales $2.5M; $0.5M royalties). Combined with a strong reported gross margin (~74.7%), this supports unit economics, funds R&D and reduces the need for a direct sales infrastructure over the medium term.
GLIX1 First-in-human Initiation And Differentiated Preclinical ProfileInitiation of a GLIX1 Phase I/IIa study and first patient dosing materially de-risks the program from discovery to clinical validation. Robust brain penetration, activity in temozolomide‑resistant models and combination potential (e.g., with PARP inhibitors) expand clinical opportunity and long-term value if safety/efficacy translate clinically.
Strong IP Protection For GLIX1 Through 2040An allowed U.S. patent extending GLIX1 protection to ~2040 offers durable exclusivity across many indications. This strengthens competitive barriers, improves licensing/partnering leverage and justifies multi-year clinical investment, supporting potential long-term returns if clinical development succeeds.
Bears Say
Limited Cash Runway Into H1 2027With ~$17.4M of cash covering operations into H1 2027, short runway constrains ability to complete GLIX1 dose escalation, support PDAC enrollment and sustain parallel programs. This raises near-term financing or partnering probability, which can delay timelines and dilute upside for existing shareholders.
Persistent Negative Operating And Free Cash FlowTTM negative operating and free cash flows (~-$7.8M) and deeply negative returns on equity reflect ongoing losses. Continued negative margins necessitate external capital or sustained royalty growth, eroding equity and limiting reinvestment capacity for pivotal trials over the medium term.
Dependence On Partner Ayrmid And Limited Commercial VisibilityReliance on Ayrmid for APHEXDA commercialization reduces BioLineRx's control over sales execution and pricing. Limited disclosure on partner strategy and coverage impairs revenue visibility, making royalties sensitive to external execution, local reimbursement and partner prioritization risks over the medium term.
Bioline RX Ltd Sponsored ADR News
BLRX FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was $2.15 and its highest was $5.06 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Bioline RX Ltd Sponsored ADR’s market cap is $14.18M.
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Aug 13, 2026 which is in 54 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on May 27, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $1.04.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.15.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 4,368,295 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of $0 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 6.646%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
BLRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful clinical progress—most notably initiation and first dosing in the GLIX1 first-in-human study, supportive preclinical data including activity in temozolomide-resistant models, ASCO exposure, and accelerating APHEXDA sales via partner Ayrmid. Offsetting these positives were materially weaker financial results versus prior year (swing to a $2.6M net loss, a ~93% drop in nonoperating income), higher R&D spend tied to GLIX1, and a modest cash runway into H1 2027. Operational transparency was limited on some site activations, dosing and commercial execution by the partner. Overall, scientific and programmatic momentum is strong but financial and disclosure constraints introduce caution.View all BLRX earnings summariesBLRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(389.80% Upside)
Technical Analysis
Synlogic
―
Moleculin Biotech
―
Citius Pharmaceuticals
―
Chemomab Therapeutics
―
Passage Bio
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors